Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE is a synthetic chemical compound characterized by an L-isoleucine residue linked to an epoxide-containing moiety, specifically a (2S,3S)-3-(ethoxycarbonyl)oxiran-2-yl carbonyl group. The oxirane (epoxide) ring is a common electrophilic warhead found in irreversible enzyme inhibitors, particularly those targeting proteases, such as cysteine proteases. This structural feature suggests that the compound likely functions by forming a covalent adduct with a nucleophilic residue in the enzyme's active site, leading to irreversible inhibition. While specific clinical development or primary indications for this exact compound are not widely reported, its chemical structure is consistent with that of a research compound designed to modulate enzymatic activity, potentially as a protease inhibitor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE.